东圣DonGSHEnG品牌怎么样 申请店铺

我要投票 东圣DonGSHEnG在化肥行业中的票数:372 更新时间:2025-08-22
东圣DonGSHEnG是哪个国家的品牌?「东圣DonGSHEnG」是 湖北东圣化工集团有限公司 旗下著名品牌。该品牌发源于湖北省宜昌市,由创始人黄斌在1998-08-06期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力东圣DonGSHEnG品牌出海!将品牌入驻外推网,定制东圣DonGSHEnG品牌推广信息,可以显著提高东圣DonGSHEnG产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

东圣DonGSHEnG怎么样

湖北东圣化工集团位于嫘祖故里宜昌远安县嫘祖镇荷花工业园,地处宜昌市远安县与保康县省道交汇处,距宜昌长江水运码头73公里,距焦枝铁路当阳岩屋庙火车站70公里,距远安县城30公里,水陆交通便利。

公司自1998年组建以来,坚持科学发展观,秉承“敢闯敢冒、做大做强、求真务实、有诺必践、回报社会”的东圣精神,按照“矿肥结合、矿化结合”的发展思路,立足资源优势,致力于磷矿深加工。2004年1月公司动工兴建30万吨/年磷酸一铵配套6000KW/h余热发电项目,一期工程规模为年产10万吨磷酸一铵,2005年4月投产,二期工程规模为年产20万吨磷酸一铵,2006年2月投产,形成了年产40万吨硫酸、15万吨磷酸、30万吨磷酸一铵的生产能力,2008年4月,公司积极应对湖北省、宜昌市关于加强磷矿资源管理促进磷化工产业发展的宏观政策调整,积极走采选加一体化之路,投资15亿元,兴建了代表国内化肥产业先进技术水平的“836”工程(80万吨硫酸、30万吨磷酸、60万吨磷酸二铵),并于2010年9月顺利投产。

经过20年的建设和发展,从一个总资产仅70万元的矿粉加工小作坊发展成现具有年产200万吨磷矿石、150万吨选矿、50万吨磷酸一铵、60万吨磷酸二铵、10万吨合成氨、15万吨尿素生产能力的大型磷化工企业集团。公司拥有宜昌东圣磷复肥有限责任公司、湖北东圣丹江化工有限公司、宜昌东禾化肥有限公司 、湖北东圣农业生产资料有限公司等8家核心控股子公司。

东圣集团一贯坚持科学发展观,秉承“敢创敢冒、做大做强、求真务实、有诺必践、回报社会”的东圣精神,按照“矿肥结合、酸肥结合”的发展思路,立足资源优势,倾力打造磷化工产学研、采选加一体化、循环利用资源的产业链条,走发展磷化工、煤化工、精细化的磷化工产业集群集团之路。

“十三五”时期,我公司将继续认真贯彻落实科学发展观,大力推进节能减排,发展循环经济和绿色经济,紧紧围绕磷矿资源的开发利用做大做强,不断向精细磷化工方向迈进,全面提高经济运行质效和企业综合实力,着力打造百亿东圣和百年东圣。


Hubei Dongsheng chemical industry group is located in the Hehua Industrial Park, Leizu Town, Yuanan County, Yichang, the hometown of Leizu. It is located at the intersection of the provincial roads of Yuanan county and Baokang County, Yichang city. It is 73 kilometers away from the Yangtze River water transport terminal of Yichang City, 70 kilometers away from Dangyang yanwumiao railway station of Jiaozhi railway, 30 kilometers away from Yuanan County, with convenient water and land transportation. Since its establishment in 1998, the company adheres to the scientific development concept, adheres to the Dongsheng spirit of "dare to venture, grow bigger and stronger, be realistic and pragmatic, have promise to practice, and return to the society", and is committed to the deep processing of phosphate rock based on resource advantages in accordance with the development idea of "combination of mineral fertilizer and mineralization". In January 2004, the company started the construction of 300000 t / a monoammonium phosphate supporting 6000kW / h waste heat power generation project. The first phase of the project has an annual output of 100000 t / a monoammonium phosphate, which was put into operation in April 2005, the second phase has an annual output of 200000 t / a monoammonium phosphate, which was put into operation in February 2006, forming a production capacity of 400000 T / a sulfuric acid, 150000 T / a phosphoric acid and 300000 t / a monoammonium phosphate. In April 2008, the company actively responded Hubei Province and Yichang City have adjusted their macro policies on strengthening the management of phosphate mineral resources and promoting the development of phosphate chemical industry. They have actively taken the road of integration of mining, beneficiation and processing, invested 1.5 billion yuan, built the "836" project (800000 tons of sulfuric acid, 300000 tons of phosphoric acid and 600000 tons of diammonium phosphate) which represents the advanced technology level of domestic fertilizer industry, and put it into operation successfully in September 2010. After 20 years of construction and development, from a small workshop of mineral powder processing with a total asset of only 700000 yuan, it has developed into a large-scale phosphate industry group with an annual production capacity of 2 million tons of phosphate ore, 1.5 million tons of beneficiation, 500000 tons of monoammonium phosphate, 600000 tons of diammonium phosphate, 100000 tons of synthetic ammonia and 150000 tons of urea. The company has 8 core holding subsidiaries, including Yichang Dongsheng phosphate compound fertilizer Co., Ltd., Hubei Dongsheng Danjiang Chemical Co., Ltd., Yichang Donghe chemical fertilizer Co., Ltd., and Hubei Dongsheng agricultural means of production Co., Ltd. Dongsheng Group always adheres to the scientific development concept, adheres to the Dongsheng spirit of "dare to create, dare to take risks, be bigger and stronger, be realistic and pragmatic, promise to practice, and return to the society", according to the development idea of "combination of mineral fertilizer and acid fertilizer", based on the resource advantages, strives to build the industrial chain of phosphorus chemical industry, research, mining, separation and integration, and recycling resources, and develops phosphorus chemical industry, coal chemical industry, and fine chemical industry The way to refine the phosphorus chemical industry cluster group. During the "13th five year plan" period, our company will continue to implement the scientific development concept, vigorously promote energy conservation and emission reduction, develop circular economy and green economy, closely focus on the development and utilization of phosphate rock resources, continue to move towards the direction of fine phosphate chemical industry, comprehensively improve the quality and efficiency of economic operation and the comprehensive strength of the enterprise, and strive to build ten billion Dongsheng and one hundred year Dongsheng.

本文链接: https://brand.waitui.com/73298d74c.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

德国第二季度GDP被下修,萎缩幅度超过最初估计

德国第二季度经济萎缩幅度超过最初估计,制造企业的表现远逊于预期。统计部门周五公布,当季国内生产总值(GDP)环比下降0.3%,初值为下降0.1%。投资也是一大拖累因素,下降了1.4%,而私人消费对GDP的支撑作用远低于最初估计。(新浪财经)

2小时前

恒大地产广东公司被广州市中级人民法院裁定破产清算

8月22日,广州市中级人民法院在全国企业破产重整案件信息网发布公告称,该院已于8月20日裁定受理恒大地产集团广东房地产开发有限公司(下称“恒大地产广东公司”)破产清算一案,并依法指定清算组担任恒大地产广东公司管理人,恒大地产广东公司的债权人应在2025年11月20日前,向恒大地产广东公司管理人申报债权。这意味着,恒大地产广东公司已依法进入破产程序。(澎湃)

2小时前

英伟达要求部分零部件供应商暂停生产H20芯片,外交部回应

外交部发言人毛宁主持例行记者会。彭博社记者提问,据报道称,英伟达已要求部分零部件供应商暂停生产H20芯片。外交部对有关英伟达停止H20芯片生产的最新报道有何评论?对此,毛宁表示:“这个问题建议你向中方的主管部门了解。作为原则,我们一贯认为各方各国都应当共同维护全球产供链的稳定畅通。”(澎湃)

2小时前

东百集团:上半年归母净利润7155.67万元,同比增长2.40%

36氪获悉,东百集团发布半年报。财报显示,公司上半年实现营业收入9.29亿元,同比增长0.11%;归属于上市公司股东的净利润7155.67万元,同比增长2.40%;基本每股收益0.0823元。

2小时前

新诺威:控股子公司SYS6036注射液获得药物临床试验批准通知书

36氪获悉,新诺威公告,公司控股子公司巨石生物近日收到国家药品监督管理局核准签发的关于SYS6036注射液的《药物临床试验批准通知书》,同意按生物类似药开展临床试验。SYS6036注射液是一款肿瘤免疫治疗的人源化单克隆抗体药物,预计将适用于治疗多种肿瘤。但需注意,药物在获得《药物临床试验批准通知书》后,尚需开展临床试验,并经国家监管部门批准后方可上市、销售。同时,药物研发存在高投入、高风险、周期长等特点,存在多种风险。短期对巨石生物及公司业绩不会产生重大影响。

2小时前

本页详细列出关于东圣DonGSHEnG的品牌信息,含品牌所属公司介绍,东圣DonGSHEnG所处行业的品牌地位及优势。
咨询